6-[F-18]fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with 123I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 10, 2009, Pages 3922-3930

  Fiebrich, Helle Brit ^a   Brouwers, Adrienne H ^a   Kerstens, Michiel N ^a   Pijl, Milan E J ^b   Kema, Ido P ^a   De Jong, Johan R ^a   Jager, Pieter L ^c   Elsinga, Philip H ^a   Dierckx, Rudi A J O ^a   Van Der Wal, Jacqueline E ^a   Sluiter, Wim J ^a   De Vries, Elisabeth G E ^a   Links, Thera P ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MARTINI HOSPITAL   (Netherlands)

^c HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 3 O METHYLDOPAMINE; 6 FLUORODOPA F 18; CATECHOLAMINE; CHROMOGRANIN A; METADRENALIN;

ADOLESCENT; ADRENAL HYPERPLASIA; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; GANGLIONEUROMA; GOLD STANDARD; HUMAN; IMAGE ANALYSIS; IMAGING; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TUMOR LOCALIZATION;

EID: 70349904742     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-1054     Document Type: Article

References (37)

1. Lenders JW, Eisenhofer G, Mannelli M, Pacak K 2005 Phaeochromocytoma. Lancet 20:665-675
2. Eisenhofer G, Bornstein SR, Brouwers FM, Cheung NK, Dahia PL, de Krijger RR, Giordano TJ, Greene LA, Goldstein DS, Lehnert H, Manger WM, Maris JM, Neumann HP, Pacak K, Shulkin BL, Smith DI, Tischler AS, Young Jr WF 2004 Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer 11:423-436 (Pubitemid 39331275)
3. Brink I, Hoegerle S, Klisch J, Bley TA 2005 Imaging of pheochromocytoma and paraganglioma. Fam Cancer 4:61-68
4. Ilias I, Pacak K 2004 Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab 89:479-491 (Pubitemid 38269845)
5. Pacak K, Eisenhofer G, Ahlman H, Bornstein SR, Gimenez-Roqueplo AP, Grossman AB, Kimura N, Mannelli M, McNicol AM, Tischler AS 2007 Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab 3:92-102 (Pubitemid 46146962)
6. Timmers HJ, Kozupa A, Chen CC, Carrasquillo JA, Ling A, Eisenhofer G, Adams KT, Solis D, Lenders JW, Pacak K 2007 Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol 25:2262-2269 (Pubitemid 46954653)
7. van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW, van de Meiracker AH, Boomsma F, Stijnen T, Krenning EP, Bosman FT, Kwekkeboom DJ 2001 [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 86: 685-693 (Pubitemid 32207482)
8. Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC 1999 Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy- D-glucose PET. Radiology 212:35-41 (Pubitemid 29302508)
9. Ilias I, Yu J, Carrasquillo JA, Chen CC, Eisenhofer G, Whatley M, McElroy B, Pacak K 2003 Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab 88:4083-4087 (Pubitemid 37153702)
10. Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I, Reincke M, Moser E, Neumann HP 2002 Pheochromocytomas: detection with 18F DOPAwhole body PET-initial results. Radiology 222:507-512 (Pubitemid 34106126)
11. Taïeb D, Tessonnier L, Sebag F, Niccoli-Sire P, Morange I, Colavolpe1 C, De Micco C, Barlier A, Palazzo FF, Henry JF, Mundler O 2008 The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal pheochromocytomas. Clinical Endocrinology 69: 580-586
12. Timmers HJ, Hadi M, Carrasquillo JA, Chen CC, Martiniova L, Whatley M, Ling A, Eisenhofer G, Adams KT, Pacak K 2007 The effects of carbidopa on uptake of 6-18F-fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. J Nucl Med 48:1599-1606 (Pubitemid 47572706)
13. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas. J Nucl Med 50:513-519
14. Ilias I, Chen CC, Carrasquillo JA, Whatley M, Ling A, Lazurová I, Adams KT, Perera S, Pacak K 2008 Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111Inpentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med 49:1613-1619
15. 2007 MIBG-scintigrafie. In: Barneveld PC, Van Urk P, eds. Aanbevelingen nucleaire geneeskunde. Neer, The Netherlands: Kloosterhof Acquisitie Services; 60-63
16. De Vries EFJ, Luurtsema G, Brussermann M, Elsinga PH, Vaalburg W1999 Fully automated synthesis module for the high yield one-pot preparation of 6-[18F]fluoro-L-DOPA. Appl Radiat Isot 51:389-394
17. Ishikawa T, Dhawan V, Chaly T, Robeson W, Belakhlef A, Mandel F, Dahl R, Margouleff C, Eidelberg D 1996 Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis. J Cereb Blood Flow Metab 16:854-863 (Pubitemid 26292053)
18. Orlefors H, Sundin A, Lu L, Oberg K, Långström B, Eriksson B, Bergström M 2006 Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomography. Eur J Nucl Med Mol Imaging 33:60-65 (Pubitemid 41785310)
19. Cecchin D, Lumachi F, Marzola MC, Opocher G, Scaroni C, Zucchetta P, Mantero F, Bui F 2006 A meta-iodobenzylguanidine scintigraphic scoring system increases accuracy in the diagnostic management of pheochromocytoma. Endocr Relat Cancer 13:525-533 (Pubitemid 43886674)
20. Berkowitz A, Basu S, Srinivas S, Sankaran S, Schuster S, Alavi A 2008 Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET. Nucl Med Commun 29:521-526 (Pubitemid 351643419)
21. Thie JA 2004 Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med 45:1431-1434
22. Erdi YE, Mawlawi O, Larson SM, Imbriaco M, Yeung H, Finn R, Humm JL 1997 Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer 80:2505-2509 (Pubitemid 28009506)
23. Koopmans KP, de Vries EG, Kema IP, Elsinga PH, Neels OC, Sluiter WJ, van der Horst-Schrivers AN, Jager PL 2006 Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol 7:728-734
24. Koopmans KP, Neels OC, Kema IP, Elsinga PH, Sluiter WJ, Vanghillewe K, Brouwers AH, Jager PL, de Vries EG 2008 Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy- phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol 26:1489-1495
25. de Jong WH, Graham KS, van der Molen JC, Links TP, Morris MR, Ross HA, de Vries EG, Kema IP 2007 Plasma free metanephrine measurement using automated online solid-phase extraction HPLC tandem mass spectrometry. Clin Chem 53:1684-1693
26. Kema IP, Meiborg G, Nagel GT, Stob GJ, Muskiet FA 1993 Isotope dilution ammonia chemical ionization mass fragmentographic analysis of urinary 3-O-methylated catecholamine metabolites. Rapid sample clean-up by derivatization and extraction of lyophilized samples. J Chromatogr 617:181-189 (Pubitemid 23248362)
27. Eisenhofer G, Lenders JW, Goldstein DS, Mannelli M, Csako G, Walther MM, Brouwers FM, Pacak K 2005 Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines. Clin Chem 51:735-744 (Pubitemid 40463925)
28. National Cancer Institute 2008 National Cancer Institute: PDQ: pheochromocytoma treatment, March 2008 update. http:// www.cancer.gov/ cancertopics/pdq/treatment/pheochromocytoma/ HealthProfessional/
29. Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE 1992 A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 13:513-521
30. Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, Keiser HR, Goldstein DS, EisenhoferG2002 Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 287: 1427-1434
31. Ilias I, Shulkin B, Pacak K 2005 New functional imaging modalities for chromaffin tumors, neuroblastomas and ganglioneuromas. Trends Endocrinol Metab 16:66-72 (Pubitemid 40270852)
32. Zelinka T, Timmers HJ, Kozupa A, Chen CC, Carrasquillo JA, Reynolds JC, Ling A, Eisenhofer G, Lazúrová I Adams KT, Whatley MA, Widimsky Jr J, Pacak K 2008 Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations. Endocr Relat Cancer 15:311-323
33. Kölby L, Bernhardt P, Levin-Jakobsen AM, Johanson V, Wängberg B, Ahlman H, Forssell-Aronsson E, Nilsson O 2003 Uptake of metaiodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters. Br J Cancer 89:1383-1388 (Pubitemid 37368903)
34. Cleary S, Brouwers FM, Eisenhofer G, Pacak K, Christie DL, Lipski J, McNeil AR, Phillips JK 2005 Expression of the noradrenaline transporter and phenylethanolamine N-methyltransferase in normal human adrenal gland and phaeochromocytoma. Cell Tissue Res 322:443-453
35. Lemmer K, Ahnert-Hilger G, Höpfner M, Hoegerle S, Faiss S, Grabowski P, Jockers-Scherubl M, Riecken EO, Zeitz M, Scherübl H 2002 Expression of dopamine receptors and transporter in neuroendocrine gastrointestinal tumor cells. Life Sci 71:667-678 (Pubitemid 34628828)
36. Eisenhofer G, Huynh TT, Hiroi M, Pacak K 2001 Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma. Rev Endocr Metab Disord 2:297-311 (Pubitemid 33640579)
37. Eisenhofer G, Keiser H, Friberg P, Mezey E, Huynh TT, Hiremagalur B, Ellingson T, Duddempudi S, Eijsbouts A, Lenders JWM 1998 Plasma metanephrines are markers of pheochromocytoma produced by catechol-o-methyltransferase within tumors. J Clin Endocrinol Metab 83:2175-2185 (Pubitemid 28496356)